ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1436

Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab

Virginia Ruiz-Esquide1, Carla Bastida2, Mariona Pascal3, Jordi Yagüe3, Dolors Soy2 and Raimon Sanmartí1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Pharmacy Service, Hospital Clínic de Barcelona, Barcelona, Spain, 3Immunology Service, Hospital Clínic de Barcelona, b, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Rheumatoid arthritis (RA), serologic tests, therapy and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). There is great variability in intravenous (iv) TCZ serum concentrations among individuals. Moreover, initial drug dosage approver by Regulatory Agencies (FDA and EMA) differes. Empirical dose de-escalation strategies are being fostered in patients with disease remission.

The purpose of the study was to examine TCZ serum concentrations at the different prescribed doses in RA. Secondary objectives were to evaluate the relationship between drug serum concentrations and laboratory parameters of disease activity.

Methods:

Prospective, observational, single-center study conducted in a university tertiary hospital. Enrolled RA patients received iv TCZ at a dose range from 4 to 8 mg/kg every 28 days. Demographic characteristics and clinical laboratory data were obtained at study entry. Blood samples for drug concentration testing were collected from the third TCZ dose onwards, just before TZC infusion and, when possible, once a week until the next drug administration.

Results:

A total of 35 patients (88.6% women, 80% Caucasian) were included. Mean age ± SD was 54.1 ± 12.3 and the median [range] of disease duration was 11.1 [2.9-48.5]. Median [range] treatment duration with iv TCZ was 36.5 [3-68] months. 54% of patients received the standard dose of 8 mg/kg whereas the rest received reduced doses (23% were on 6 mg/kg and 23% on 4 mg/kg) due to persistent remission/low disease activity. 20 patients (57.1%) were being treated with low steroid dose and 24 (68.6%) were on concomitant DMARD, mainly methotrexate.

Regarding drug concentration testing, a total of 109 samples were obtained. Nineteen patients participated to multiple drug sampling between two drug administrations and in the 17 remaining patients, a pre-dose sample was drawn. Mean TCZ concentrations are displayed in table 1. No significant differences were observed in median pre-dose TCZ concentration values (54 samples) between patients on 8 and 6 mg/kg whereas significant lower drug levels were observed in those taking 4 mg/kg.

According to inflammatory parameters, mean C-reactive protein (CRP) concentration was significantly lower in those patients with trough TCZ concentrations >1 µg/mL compared to those <1 µg/mL (0.066 mg/dL vs 0.689 mg/dL, respectively; p<0.001). This difference was not observed with calprotectin serum concentrations (2.260 µg/mL vs 2.143 µg/mL).

Conclusion:

Trough TCZ serum concentrations do not differ between patients on an 8 and 6 mg/kg regimen. Therefore, according to the pharmacokinetics observed in our study, a maintenance dose of iv TCZ 6 mg/kg would be appropriate for most RA patients. Although CRP levels are significantly higher in patients with trough iv TCZ concentrations <1 µg/mL, serum calprotectin did not show the same tendency.

Table 1. Mean (± standard deviation) intravenous tocilizumab serum concentrations at different prescribed doses within time.

Time (days)

TCZ 8 mg/kg

TCZ 6 mg/kg

TCZ 4 mg/kg

Pre-infusion (Ctrough)

8.91 ± 6.0

5.68 ± 9.1

0.79 ± 1.2

T7

84.82 ± 33.9

48.88 ± 18.6

26.06 ± 6.4

T14

46.40 ± 19.8

30.98 ± 11.5

15.16 ± 5.3

T21

21.63 ± 9.5

19.65 ± 10.5

7.11 ± 4.4

T28 (Ctrough)

10.63 ± 7.3

10.29 ± 10.8

1.32 ± 2.3


Disclosure: V. Ruiz-Esquide, None; C. Bastida, None; M. Pascal, None; J. Yagüe, None; D. Soy, None; R. Sanmartí, None.

To cite this abstract in AMA style:

Ruiz-Esquide V, Bastida C, Pascal M, Yagüe J, Soy D, Sanmartí R. Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/therapeutic-drug-monitoring-on-rheumatoid-arthritis-patients-with-reduced-doses-of-intravenous-tocilizumab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-drug-monitoring-on-rheumatoid-arthritis-patients-with-reduced-doses-of-intravenous-tocilizumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology